drugset
drugset / Trial / NCT04885972

Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis

NCT04885972 ↗

Phase 2 Unknown 124 enrolled Sorrento Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study evaluates the efficacy and safety of a single IA injection of various RTX doses, Zilretta or placebo for the treatment of pain due to moderate to severe osteoarthritis knee pain..

Timeline

Start
2021-11-15
Primary completion
2023-09
Completion
2023-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Resiniferatoxin Other / unclassified 7.5 ug Other
Subject Resiniferatoxin Other / unclassified 10 ug Other
Subject Resiniferatoxin Other / unclassified 12.5 ug Other
Subject Resiniferatoxin Other / unclassified 15 ug Other
Subject Resiniferatoxin Other / unclassified 20 ug Other
Comparator Triamcinolone Acetonide Other / unclassified 32 mg Other

Indications

osteoarthritis, knee